Show simple item record

dc.contributor.authorKim, Dong Won
dc.contributor.authorMiller, Ann
dc.contributor.authorLi, Andrew
dc.contributor.authorHardy, Naomi
dc.contributor.authorSilver, Kristi D
dc.date.accessioned2021-06-09T18:29:25Z
dc.date.available2021-06-09T18:29:25Z
dc.date.issued2021-01-07
dc.identifier.urihttp://hdl.handle.net/10713/15970
dc.description.abstractHypercalcemia is a common finding in patients who have an underlying malignancy. Only a few cases of hypercalcemia of malignancy have been linked to more than one mechanism of hypercalcemia. Here, we present a patient with liposarcoma and hypercalcemia of malignancy in the setting of simultaneous elevations in parathyroid hormone-related peptide (PTHrP) and 1,25 dihydroxyvitamin D [1,25(OH)2D] levels. Sarcoma-associated hypercalcemia is a rare disorder.en_US
dc.description.urihttps://doi.org/10.1016/j.aace.2020.11.037en_US
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofAACE clinical case reportsen_US
dc.rights© 2021Published by Elsevier Inc. on behalf of the AACE.en_US
dc.subject1,25 dihydroxyvitamin Den_US
dc.subject1,25(OH)2D, 1,25 Dihydroxyvitamin Den_US
dc.subjectPTHrPen_US
dc.subjectPTHrP, parathyroid hormone-related peptideen_US
dc.subjecthypercalcemia of malignancyen_US
dc.subjectsarcomaen_US
dc.titleHypercalcemia of Malignancy: Simultaneous Elevation in Parathyroid Hormone-Related Peptide and 1,25 Dihydroxyvitamin D in Sarcomaen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.aace.2020.11.037
dc.identifier.pmid34095480
dc.source.volume7
dc.source.issue3
dc.source.beginpage169
dc.source.endpage173
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record